Poor
Non-Compliant
Patient Risk:
Moderate
Summary
Only the IV infusion/administration assertion is supported by the provided label excerpts. Multiple claims about lack of antacid-related interactions, absence of stomach-pH dependence, and clinical management of antacids are not supported by the supplied label text (including an unavailable drug-interactions section).
Category Scores
Accurate Statements
Tigecycline is administered by intravenous (IV) infusion.
Supported by label excerpts indicating intravenous infusion administration (2.5 Preparation and Administration; 12.3 Pharmacokinetics).
Unsupported Statements
Because tigecycline is administered IV infusion, its effect does not depend on how much drug is absorbed through the stomach or intestines.
The provided label excerpts do not explicitly support this mechanistic conclusion.
Typical oral antacids are not expected to affect tigecycline’s efficacy.
Section 7 drug-interaction text is not provided; no supported label statement is available.
Because tigecycline is administered IV, there is no need for gastric acid processing to start its action.
The provided label excerpts do not explicitly address gastric acid processing or the stated conclusion.
No interaction mechanism tied to stomach pH is expected between antacids and tigecycline.
Not supported by the provided label excerpts; drug-interaction section content is unavailable.
The main practical interaction issue for tigecycline is less about antacids and more about how tigecycline is prepared and administered (e.g., compatibility with IV lines/solutions).
While compatibility/preparation guidance exists, the claim that antacids are not a main practical issue is not supported by the provided excerpts.
Antacids do not change tigecycline’s IV delivery.
Label excerpts provided cover infusion/compatibility but do not support the specific claim about antacids affecting IV delivery.
Patients can generally continue prescribed antacid therapy unless their care team has a specific reason to stop or adjust it.
No supporting labeled interaction/management guidance is present in the provided excerpts (and section 7 text is unavailable).
If an antacid is used with another antibiotic or oral medication, the antacid could interact with those other drugs.
Not supported as a tigecycline-labeled statement; no relevant label text is provided.
For tigecycline itself, the IV route prevents the usual 'reduced absorption due to higher stomach pH' interaction pattern seen with many oral agents.
The provided label excerpts do not explicitly support the described interaction-pattern exclusion.
Contradictions
Important Omissions
No evaluation/claims coverage for labeled boxed warnings, contraindications, warnings/precautions, or monitoring recommendations for tigecycline (not required to answer antacid questions but material for label adherence completeness).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Speculative or unsupported claims about antacid interactions and stomach-pH dependence could lead to inaccurate medication-management decisions regarding concomitant antacid use, especially because the drug-interactions label text was not provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Non-Compliant
Primary Issue
Multiple mechanistic and clinical management claims about antacids (lack of stomach-pH dependence, lack of interaction impact, and continuation guidance) are not supported by the provided label excerpts; section 7 drug-interactions content is missing, preventing verification.
Suggested Improvement
Restrict claims to label-supported administration/preparation and compatibility statements; remove or qualify all antacid/stomach-pH interaction mechanistic assertions and any guidance about continuing or stopping antacids unless the exact labeled drug-interactions text (section 7) is provided and matches the claim.